Is indoramin an effective alternative to prostatectomy?

Area of Science:

• Urology
• Pharmacology

Background:

• Alpha-1-adrenergic antagonists are used for symptomatic treatment in patients awaiting prostate surgery.
• Previous studies confirmed their efficacy in placebo-controlled trials.
• No direct comparison existed between these drugs and subsequent prostatectomy outcomes.

Purpose of the Study:

• To compare the efficacy of indoramin with prostatectomy in patients awaiting surgery.
• To assess symptom scores and peak urinary flow rates.
• To evaluate the predictive value of indoramin response for prostatectomy outcomes.

Main Methods:

• Fifty-five patients awaiting prostatectomy were assessed.
• Measurements included symptom scores and peak urinary flow rates.
• Patients were evaluated before treatment, during indoramin treatment, and two months post-prostatectomy.

Main Results:

• 36% of patients experienced side effects with indoramin.
• Indoramin provided overall symptom improvement, but 26-30% saw no relief.
• Prostatectomy yielded significantly greater symptomatic relief and peak flow rate increase (11.7 ml/s) compared to indoramin (3.2 ml/s).
• Five patients preferred indoramin over surgery.

Conclusions:

• Indoramin is not a substitute for prostatectomy.
• While it may offer temporary relief, side effects and inconsistent efficacy limit its use.
• Response to indoramin does not accurately predict prostatectomy outcomes.